Alessandro Brigo

Roche (Switzerland) — Switzerland

Computer Science · Physical Sciences

18h-index2.0kcitations49works4.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(29), Melanoma and MAPK Pathways(15), Protein Kinase Regulation and GTPase Signaling(10), Carcinogens and Genotoxicity Assessment(10), HIV/AIDS drug development and treatment(4)

Publications49 total

P03-04 Leveraging Large Language Models and Multi-Agent Systems to Extract Discontinuation Rationales in Drug Development
Toxicology Letters·2025
Preclinical pharmacology of alogabat: a novel GABAA-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired GABAA signaling
Frontiers in Pharmacology·2025· 1 citedOpen Access
SARM1 base-exchange inhibitors induce SARM1 activation and neurodegeneration at low doses
npj Drug Discovery.·2025· 3 citedOpen Access
SARM1 base-exchange inhibitors induce SARM1 activation and neurodegeneration at low doses
2025· 3 citedOpen Access
Discovery of a Potent SARM1 Base-Exchange Inhibitor with In Vivo Efficacy
Journal of Medicinal Chemistry·2025· 7 cited
Data-driven federated learning in drug discovery with knowledge distillation
Nature Machine Intelligence·2025· 16 cited
P05-15 Large language models in drug development: deciphering discontinuationc causes to inform future strategies
Toxicology Letters·2024
Assessing the utility of common arguments used in expert review of in silico predictions as part of ICH M7 assessments
Regulatory Toxicology and Pharmacology·2023· 6 cited
Federated Learning in Computational Toxicology: An Industrial Perspective on the Effiris Hackathon
Chemical Research in Toxicology·2023· 16 citedOpen Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Table from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Table from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Jürgen Wichmann(15), Caroline Rynn(15), Thomas Friess(15), Jeannine Petrig-Schaffland(15), Martin Kornacker(15), Jasmin Emmenegger(15), Jan Eckmann(15), Frank Herting(15), Nicolas Frances(15), Daniel Hunziker(15), Daniela Krummenacher(15), Dominik Rüttinger(15), Alison Ribeiro(15), Marina Bacac(15), David S. Hewings(15), Reinhard Dummer(15), Gabriel Schnetzler(15), Bruno Martoglio(15), James R. Bischoff(15), Piergiorgio Pettazzoni(15)